Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Trillium Therapeutics Inc. (TRIL)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/07/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 11/25/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 11/16/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 11/12/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 11/02/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 10/05/2020 |
6-K
| Quarterly results |
| 09/18/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 09/16/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 09/10/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"FORM 6-K",
"Offering Opinion",
"TRILLIUM ANNOUNCES PRICING OF US$130 MILLION PUBLIC OFFERING OF COMMON SHARES CAMBRIDGE, MA, September 10, 2020 - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 10,000,000 common shares of the Company . The Common Shares are being sold at a public offering price of US$13.00 per Common Share. In connection with the Offering, Trillium has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 Common Shares. The gross proceeds to the Company from the Offering are expected to be approximately US$130 million, before deducting underwriting discounts and commissions and other estimated offering e...",
"Underwriting Agreement" |
|
| 09/08/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 08/12/2020 |
6-K
| Quarterly results |
| 07/30/2020 |
6-K
| Quarterly results |
| 07/06/2020 |
6-K
| Quarterly results |
| 05/29/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 05/26/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 05/15/2020 |
6-K
| Quarterly results |
| 05/13/2020 |
6-K
| Quarterly results |
| 05/06/2020 |
6-K
| Quarterly results |
| 05/05/2020 |
6-K
| Quarterly results |
| 04/23/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 04/08/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 03/10/2020 |
6-K
| Quarterly results |
| 02/28/2020 |
6-K
| Quarterly results |
| 02/07/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"FORM 6-K",
"TRILLIUM THERAPEUTICS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS • Paul Walker of New Enterprise Associates is appointed to the Board of Directors CAMBRIDGE, MA, February 7, 2020 - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Paul Walker has been appointed to the Company's Board of Directors, and Dr. Ali Behbahani has been appointed as a Board Observer, effective February 6, 2020. "We are delighted to welcome Mr. Walker to the Board of Directors and Dr. Behbahani as a Board Observer, and look forward to their guidance as we work to bring to patients our CD47 programs," stated Dr. Robert Kirkman, Executive Chair of Trillium Therapeutics. "We are excited about Trillium's recent progres...",
"Material Change Report",
"Material Change Report" |
|
| 01/29/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 01/23/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 01/23/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 01/22/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 01/16/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 01/07/2020 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: |
| 11/14/2019 |
6-K
| Quarterly results |
| 11/06/2019 |
6-K
| Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:|
Docs:
|
"FORM 6-K",
"TRILLIUM THERAPEUTICS TO REPORT PRECLINICAL DATA ON ITS STING PROGRAM AT THE SITC 34 TH ANNUAL MEETING TORONTO, November 6, 2019 - Trillium Therapeutics Inc. , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that new preclinical data from its STING agonist program will be presented at the 34 th annual meeting of the Society for Immunotherapy of Cancer . The meeting will be held November 6-10 in National Harbor, MD. The poster presentation will highlight the anti-tumor activity of TTI-10001, a novel small molecule STING agonist, when delivered intravenously or orally. Details of the presentation are listed below. Title: "TTI-10001, a next generation small molecule STING agonist, demonstrates potent anti-tumor activity in ..." |
|
| 10/22/2019 |
6-K
| Quarterly results |
| 10/08/2019 |
6-K
| Quarterly results |
|
|
|